Evolutionary Genomics Inc
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governme… Read more
Evolutionary Genomics Inc (FNAM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2022: 0.034x
Based on the latest financial reports, Evolutionary Genomics Inc (FNAM) has a cash flow conversion efficiency ratio of 0.034x as of December 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-188.48K) by net assets ($-5.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evolutionary Genomics Inc - Cash Flow Conversion Efficiency Trend (2009–2022)
This chart illustrates how Evolutionary Genomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Evolutionary Genomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evolutionary Genomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Torah Cement
EGX:TORA
|
N/A |
|
ConectiSys Corporation
PINK:CONC
|
-0.284x |
|
Life Is Hard SA
RO:LIH
|
N/A |
|
Arcontech Group Plc
LSE:ARC
|
0.113x |
|
Fidelity Emerging Markets Ord
LSE:FEML
|
0.103x |
|
Conn's, Inc.
NASDAQ:CONNQ
|
-0.118x |
|
Sterling Consolidated Corp
PINK:STCC
|
-0.134x |
|
Block Energy PLC
LSE:BLOE
|
0.007x |
Annual Cash Flow Conversion Efficiency for Evolutionary Genomics Inc (2009–2022)
The table below shows the annual cash flow conversion efficiency of Evolutionary Genomics Inc from 2009 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-1.57 Million | $-640.95K | 0.409x | +13.59% |
| 2021-12-31 | $-4.40 Million | $-1.58 Million | 0.360x | -71.40% |
| 2020-12-31 | $-1.83 Million | $-2.30 Million | 1.258x | -32.92% |
| 2019-12-31 | $-333.73K | $-625.98K | 1.876x | +201.09% |
| 2018-12-31 | $403.59K | $-748.84K | -1.855x | -121.21% |
| 2017-12-31 | $1.40 Million | $-1.18 Million | -0.839x | -39.59% |
| 2016-12-31 | $1.84 Million | $-1.11 Million | -0.601x | -197.07% |
| 2015-12-31 | $2.92 Million | $-590.04K | -0.202x | -954.10% |
| 2014-12-31 | $1.34 Million | $-25.80K | -0.019x | -111.25% |
| 2013-12-31 | $-77.17K | $-13.17K | 0.171x | -25.31% |
| 2012-12-31 | $-62.62K | $-14.30K | 0.228x | -58.58% |
| 2011-12-31 | $-48.50K | $-26.75K | 0.552x | -33.26% |
| 2010-12-31 | $-31.16K | $-25.75K | 0.826x | -36.90% |
| 2009-12-31 | $-7.63K | $-9.99K | 1.310x | -- |